FTC and NY sue Daraprim maker over access to samples

The Federal Trade Commission and state of New York have alleged that Vyera Pharmaceuticals broke federal antitrust laws by denying access to samples that competitors needed to replicate its infection-treating drug.

Get unlimited access to all Global Competition Review content